How many 8-K filings has Compass Therapeutics, Inc. filed?

Compass Therapeutics, Inc. (CMPX) has 11 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Compass Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Compass Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Compass Therapeutics, Inc. (CMPX) — 8-K Filings

All 8-K filings from Compass Therapeutics, Inc.. Browse 11 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (11)

8-K Filing — May 5, 2026
Compass Therapeutics Files 8-K: Material Agreement & Other Events — Aug 13, 2025 Risk: medium
On August 12, 2025, Compass Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and reported o
Compass Therapeutics Files 8-K on Shareholder Vote Matters — Jun 12, 2025 Risk: low
Compass Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders on June 11, 2025. The filing details the
Compass Therapeutics Files 8-K — Apr 1, 2025 Risk: low
Compass Therapeutics, Inc. filed an 8-K on April 1, 2025, to report on other events and financial statements. The filing does not contain specific financial fig
Compass Therapeutics Files 8-K — Jan 8, 2025 Risk: low
Compass Therapeutics, Inc. filed an 8-K on January 8, 2025, reporting on results of operations, financial condition, and other events. The filing also includes
Compass Therapeutics Appoints New Chief Medical Officer — Dec 10, 2024 Risk: medium
Compass Therapeutics, Inc. announced on December 9, 2024, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer. Dr. Michaels previously served as S
Compass Therapeutics Files 8-K on Shareholder Vote — Jun 17, 2024 Risk: low
Compass Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders on June 13, 2024. The filing details the
Compass Therapeutics Appoints New CMO, Elects Director — May 28, 2024 Risk: medium
Compass Therapeutics, Inc. announced on May 28, 2024, the appointment of Dr. Michael J. Ybarra as Chief Medical Officer and the election of Ms. Sarah E. Kelly t
Compass Therapeutics Files 8-K — Apr 25, 2024 Risk: low
Compass Therapeutics, Inc. filed an 8-K on April 25, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Compass Therapeutics Reports Executive Changes & Compensation on Jan 8 — Jan 9, 2024
Compass Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to the departure or election of directo
Compass Therapeutics Files 8-K on Financial Condition & Operations — Jan 5, 2024
Compass Therapeutics, Inc. filed an 8-K on January 5, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure.' Thi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX